30. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al. (2006) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 12: 1314–1321. 31. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, et al. (2006) The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8: 261–279. 32. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE (2008) Astrocytic regulation of human monocytic/microglial activation. J Immunol 181: 5425–5432. 33. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275–290. 34. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78. 35. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13: 265–270. 36. Keith B, Simon MC (2007) Hypoxia-induced factors, stem cells, and cancer. Cell 129: 465–472. 37. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, et al. (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1a. Oncogene 28: 3949–3959. 38. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, et al. (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 2435–2444. 39. Estrov FS, H.M. K, Harris D, Van Q, Fokt I, et al. (2001) WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21: 3777–3784. 40. Lee K, D.Z. Q, Rey S, Wei H, Liu JO, et al. (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 106: 2353–2358. 41. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760. 42. Hussain SF, Kong L-Y, Jordan J, Conrad C, Madden T, et al. (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67: 9630–9636. 43. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, et al. (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14: 5759–5768. 44. Sitkovsky M (2009) T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends in Immunology 30: 102–108. Hypoxia Potentiates Glioma Immunosuppression 45. Ohta A, Sitkovsky M (2001) Role of G-protein coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916–920. 46. Leek RD, Landers RJ, Harris AL, Lewis CE (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79: 991. 47. Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104: 2224. 48. Negus RP, Stamp GW, Hadley J, Balkwill FR (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150: 1723. 49. Grimshaw MJ, Wilson JL, Balkwill FR (2002) Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 32: 2393. 50. Barleon B, Sozzani S, Zhou D, Welch HA, Mantovani A, et al. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336. 51. Acosta-Iborra B, Elorza A, Olazabal IM, Martin-Cofreces NB, Martin-Puig S, et al. (2009) Macrophage oxygen sensing modulates antigen presentation and phagocytic functions involving IFN-gamma production through the HIF-1 alpha transcription factor. J Immunol 182: 3155–3164. 52. Anand RJ, Gribar SC, Li J, Kohler JW, Branca MF, et al. (2007) Hypoxia causes an increase in phagocytosis by macrophages in a HIF-1alpha-dependent manner. J Leukoc Biol 82: 1257–1265. 53. Owegi HO, Egot-Lemaire S, Waite LR, Waite GN (2010) Macrophage activity in response to steady-state oxygen and hydrogen peroxide concentration-biomed 2010. Biomed Sci Instrum 46: 57–62. 54. Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155–1166. 55. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, et al. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22: 657–682. 56. Murdoch C, Lewis CE (2005) Macrophage migration and gene expression in response to tumore hypoxia. Int J Cancer 117: 701–708. 57. Jordan JT, Sun WH, Hussain SF, DeAngulo G, Prabhu SS, et al. (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57: 123–131. 58. Bodor J, Fehervari Z, Diamond B, Sakaguchi S (2007) ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol 37: 884–895. PLoS ONE | www.plosone.org 12 January 2011 | Volume 6 | Issue 1 | e16195